Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free SKIN Stock Alerts

Beauty Health (SKIN) Financials

Beauty Health logo
$0.86 +0.02 (+2.66%)
Closing price 04:00 PM Eastern
Extended Trading
$0.85 -0.01 (-1.27%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Beauty Health

Annual Income Statements for Beauty Health

This table shows Beauty Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.64 -29 -379 44 -100 -29 -9.52
Consolidated Net Income / (Loss)		 -1.64 -29 -379 44 -100 -29 -9.52
Net Income / (Loss) Continuing Operations		 -1.64 -29 -379 44 -100 -29 -9.52
Total Pre-Tax Income 		-2.94 -38 -381 45 -102 -30 -5.94
Total Operating Income		 13 -17 -40 -26 -131 -68 -21
Total Gross Profit		 107 67 179 249 155 182 196
Total Revenue		 167 119 260 366 398 334 301
Operating Revenue		 - 119 260 366 398 334 301
Total Cost of Revenue		 60 52 82 117 243 152 104
Operating Cost of Revenue		 60 52 82 117 243 152 104
Total Operating Expenses		 93 84 218 275 286 250 217
Selling, General & Admin Expense		 27 31 99 106 131 125 118
Marketing Expense		 62 50 112 160 144 118 94
Research & Development Expense		 4.61 3.41 8.20 8.44 10 6.30 5.63
Total Other Income / (Expense), net		 -16 -21 -341 71 29 38 15
Interest Expense		 - - 12 13 14 10 19
Interest & Investment Income		 -17 -21 0.04 9.18 23 17 8.95
Other Income / (Expense), net		 0.70 -0.03 -329 75 20 32 25
Income Tax Expense		 -1.30 -9.31 -1.88 1.12 -1.77 -0.45 3.58
Basic Earnings per Share		 ($0.05) ($0.85) ($3.71) $0.30 ($0.76) ($0.23) ($0.08)
Weighted Average Basic Shares Outstanding		 32.14M 34.29M 102.11M 147.55M 131.68M 123.83M 126.38M
Diluted Earnings per Share		 ($0.05) ($0.85) ($3.71) ($0.23) ($0.76) ($0.36) ($0.16)
Weighted Average Diluted Shares Outstanding		 32.14M 34.29M 102.11M 148.51M 131.68M 142.49M 135.80M
Weighted Average Basic & Diluted Shares Outstanding		 - 11.78M 150.60M 132.50M 123.43M 125.25M 127.77M

Quarterly Income Statements for Beauty Health

This table shows Beauty Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -74 -9.40 -0.68 0.20 -18 -10 -10 20 -11 -8.10 -6.63
Consolidated Net Income / (Loss)		 -74 -9.40 -0.68 0.20 -18 -10 -10 20 -11 -8.10 -6.63
Net Income / (Loss) Continuing Operations		 -74 -9.40 -0.68 0.20 -18 -10 -10 20 -11 -8.10 -6.63
Total Pre-Tax Income 		-70 -8.80 -1.34 -0.15 -16 -12 -9.20 19 -11 -4.81 -6.81
Total Operating Income		 -82 -18 -17 -22 -22 -7.16 -12 -2.70 -6.24 0.16 -1.80
Total Gross Profit		 -13 46 48 41 41 52 49 49 46 53 44
Total Revenue		 97 97 81 91 79 83 70 78 71 82 65
Operating Revenue		 97 97 81 91 79 83 70 78 71 82 65
Total Cost of Revenue		 110 51 33 50 38 31 21 29 25 29 20
Operating Cost of Revenue		 110 51 33 50 38 31 21 29 25 29 20
Total Operating Expenses		 70 64 65 63 62 60 61 52 52 53 46
Selling, General & Admin Expense		 37 29 29 31 33 32 34 27 29 28 22
Marketing Expense		 31 32 34 30 28 27 26 23 21 24 23
Research & Development Expense		 1.84 3.05 2.81 1.16 1.11 1.22 1.00 1.25 1.70 1.68 1.10
Total Other Income / (Expense), net		 12 9.56 16 22 5.17 -4.56 2.82 21 -4.40 -4.97 -5.01
Interest Expense		 3.45 3.36 3.03 2.45 2.47 2.46 2.50 4.14 6.31 6.37 6.35
Interest & Investment Income		 6.75 6.39 5.36 4.19 4.88 2.22 3.03 3.16 1.26 1.51 1.49
Other Income / (Expense), net		 8.46 6.53 13 20 2.76 -4.32 2.29 22 0.65 -0.11 -0.15
Income Tax Expense		 3.48 0.60 -0.66 -0.35 1.95 -1.39 0.89 -0.99 0.39 3.30 -0.18
Basic Earnings per Share		 ($0.56) ($0.08) ($0.01) $0.00 ($0.15) ($0.07) ($0.08) $0.16 ($0.09) ($0.07) ($0.05)
Weighted Average Basic Shares Outstanding		 132.90M 131.68M 123.12M 123.72M 124.06M 123.83M 125.08M 126.07M 126.89M 126.38M 127.79M
Diluted Earnings per Share		 ($0.56) ($0.08) ($0.10) ($0.10) ($0.15) ($0.01) ($0.08) $0.03 ($0.09) ($0.02) ($0.05)
Weighted Average Diluted Shares Outstanding		 132.90M 131.68M 144.48M 141.93M 124.06M 142.49M 125.08M 140.29M 126.89M 135.80M 131.40M
Weighted Average Basic & Diluted Shares Outstanding		 - 123.43M 123.63M 124.02M 124.12M 125.25M 125.99M 126.83M 127.50M 127.77M 129.60M

Annual Cash Flow Statements for Beauty Health

This table details how cash moves in and out of Beauty Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 3.83 2.02 893 -331 -47 -149 -143
Net Cash From Operating Activities		 1.73 -12 -28 -107 22 16 37
Net Cash From Continuing Operating Activities		 1.73 -12 -28 -107 22 16 37
Net Income / (Loss) Continuing Operations		 -1.64 -29 -379 44 -100 -29 -9.52
Consolidated Net Income / (Loss)		 -1.64 -29 -379 44 -100 -29 -9.52
Depreciation Expense		 1.38 2.55 4.49 7.16 11 9.94 3.85
Amortization Expense		 14 13 18 20 28 27 25
Non-Cash Adjustments To Reconcile Net Income		 0.76 7.65 339 -43 54 23 5.53
Changes in Operating Assets and Liabilities, net		 -13 -6.92 -10 -135 29 -15 12
Net Cash From Investing Activities		 -12 -3.82 -38 -19 -32 -6.79 -5.16
Net Cash From Continuing Investing Activities		 -12 -3.82 -38 -19 -32 -6.79 -5.16
Purchase of Property, Plant & Equipment		 -8.77 -3.50 -11 -11 -3.83 -0.76 -0.30
Acquisitions		 -3.71 -0.32 -27 -8.02 -28 -6.04 -4.86
Net Cash From Financing Activities		 15 18 959 -205 -37 -158 -175
Net Cash From Continuing Financing Activities		 15 18 959 -205 -37 -158 -175
Repayment of Debt		 -12 -17 -252 0.00 0.00 -156 -411
Repurchase of Preferred Equity		 - 0.00 0.00 0.00 -2.24 0.00 0.00
Repurchase of Common Equity		 0.00 -0.15 0.00 -160 -30 0.00 0.00
Issuance of Debt		 29 37 755 - 0.00 0.00 238
Other Financing Activities, net		 -1.77 -0.90 456 -45 -5.05 -1.96 -1.57
Cash Interest Paid		 16 14 10 9.82 9.38 8.01 14

Quarterly Cash Flow Statements for Beauty Health

This table details how cash moves in and out of Beauty Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 11 -39 -77 -95 8.02 15 1.60 -165 7.76 13 -28
Net Cash From Operating Activities		 18 -5.17 -17 6.20 10 16 3.00 9.65 9.65 15 -5.55
Net Cash From Continuing Operating Activities		 18 -5.17 -17 6.20 10 16 3.00 9.65 9.65 15 -5.55
Net Income / (Loss) Continuing Operations		 -74 -9.40 -0.68 0.20 -18 -10 -10 20 -11 -8.10 -6.63
Consolidated Net Income / (Loss)		 -74 -9.40 -0.68 0.20 -18 -10 -10 20 -11 -8.10 -6.63
Depreciation Expense		 2.51 4.34 2.77 2.66 3.06 1.45 1.86 0.71 0.64 0.64 0.56
Amortization Expense		 6.53 6.69 6.83 7.05 7.29 5.89 5.09 5.54 8.78 5.72 5.78
Non-Cash Adjustments To Reconcile Net Income		 30 8.22 -1.85 5.71 18 11 4.14 -9.53 3.77 7.16 3.87
Changes in Operating Assets and Liabilities, net		 53 -15 -24 -9.42 0.16 8.34 2.00 -6.79 7.50 9.78 -9.14
Net Cash From Investing Activities		 -4.44 -2.17 -1.80 -2.04 -2.09 -0.86 -1.15 -1.55 -1.08 -1.38 -1.65
Net Cash From Continuing Investing Activities		 -4.44 -2.17 -1.80 -2.04 -2.09 -0.86 -1.15 -1.55 -1.08 -1.38 -1.65
Purchase of Property, Plant & Equipment		 -0.17 -0.03 -0.34 -0.33 -0.00 -0.07 -0.05 -0.09 -0.03 -0.14 -0.22
Acquisitions		 -4.26 -2.14 -1.46 -1.70 -2.09 -0.79 -1.10 -1.46 -1.06 -1.24 -1.43
Net Cash From Financing Activities		 -2.35 -31 -59 -99 -0.20 -0.77 -0.25 -173 -0.80 -0.51 -21
Net Cash From Continuing Financing Activities		 -2.35 -31 -59 -99 -0.20 -0.77 -0.25 -173 -0.80 -0.51 -21
Repayment of Debt		 -0.23 -0.36 -58 -98 - -0.30 0.00 -173 -238 - -20
Other Financing Activities, net		 -2.12 -0.85 -0.87 -0.42 -0.20 -0.47 -0.25 -0.71 -0.19 -0.43 -0.75
Effect of Exchange Rate Changes		 - - - - 1.33 - - - - - -0.21

Annual Balance Sheets for Beauty Health

This table presents Beauty Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 223 1,219 1,003 929 686 500
Total Current Assets		 59 1,001 783 698 477 310
Cash & Equivalents		 9.49 902 568 523 370 233
Accounts Receivable		 19 47 76 55 28 22
Inventories, net		 23 35 110 91 69 48
Prepaid Expenses		 3.22 12 28 29 9.49 5.40
Current Deferred & Refundable Income Taxes		 4.61 4.60 1.28 0.33 0.82 1.70
Plant, Property, & Equipment, net		 0.00 16 18 14 5.98 2.54
Total Noncurrent Assets		 164 202 202 217 203 188
Goodwill		 99 124 125 126 123 127
Intangible Assets		 51 56 46 62 48 36
Noncurrent Deferred & Refundable Income Taxes		 0.27 0.33 0.82 0.53 3.89 1.93
Other Noncurrent Operating Assets		 14 22 30 28 28 23
Total Liabilities & Shareholders' Equity		 223 1,219 1,003 929 686 500
Total Liabilities		 253 917 836 870 634 439
Total Current Liabilities		 31 76 72 115 68 186
Short-Term Debt		 0.51 - - - 0.00 124
Accounts Payable		 18 29 28 45 22 16
Accrued Expenses		 2.46 15 15 20 20 15
Current Deferred & Payable Income Tax Liabilities		 0.00 0.29 1.43 2.76 3.43 1.23
Current Employee Benefit Liabilities		 9.48 29 22 22 18 25
Other Current Liabilities		 0.00 3.71 4.96 26 5.15 5.13
Total Noncurrent Liabilities		 222 840 764 755 566 252
Long-Term Debt		 216 730 734 738 552 240
Noncurrent Deferred & Payable Income Tax Liabilities		 3.99 3.56 2.01 0.70 0.40 0.39
Other Noncurrent Operating Liabilities		 1.85 107 28 16 13 12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -30 302 167 59 52 61
Total Preferred & Common Equity		 -30 302 167 59 52 61
Total Common Equity		 -30 302 167 59 52 61
Common Stock		 14 722 550 541 567 580
Retained Earnings		 -44 -419 -379 -479 -508 -517
Accumulated Other Comprehensive Income / (Loss)		 0.24 -1.26 -4.53 -3.04 -6.95 -1.43

Quarterly Balance Sheets for Beauty Health

This table presents Beauty Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 845 712 700 674 508 504 473
Total Current Assets		 615 490 485 469 306 308 278
Cash & Equivalents		 445 350 359 373 212 219 204
Accounts Receivable		 48 41 36 23 25 22 19
Inventories, net		 96 77 73 66 59 56 48
Prepaid Expenses		 26 21 16 7.18 7.79 7.43 5.39
Current Deferred & Refundable Income Taxes		 1.20 0.40 0.40 0.27 2.08 3.19 1.64
Plant, Property, & Equipment, net		 12 9.72 7.63 4.22 3.70 3.05 2.34
Total Noncurrent Assets		 218 212 207 200 198 192 193
Goodwill		 125 125 125 124 126 126 126
Intangible Assets		 58 54 51 46 43 38 33
Noncurrent Deferred & Refundable Income Taxes		 1.93 3.04 1.17 4.25 3.16 0.99 2.41
Other Noncurrent Operating Assets		 32 30 29 26 25 27 32
Total Liabilities & Shareholders' Equity		 845 712 700 674 508 504 473
Total Liabilities		 781 643 640 628 434 438 418
Total Current Liabilities		 94 75 74 63 59 62 155
Short-Term Debt		 - - - - - - 103
Accounts Payable		 37 27 23 23 23 17 16
Accrued Expenses		 24 24 28 17 14 19 19
Current Deferred & Payable Income Tax Liabilities		 3.44 2.36 1.40 3.31 2.68 1.50 0.46
Current Employee Benefit Liabilities		 15 17 17 15 15 19 13
Other Current Liabilities		 13 5.19 4.83 5.08 5.17 5.04 4.16
Total Noncurrent Liabilities		 688 567 566 565 374 376 263
Long-Term Debt		 665 551 551 553 363 363 241
Noncurrent Deferred & Payable Income Tax Liabilities		 1.07 1.06 1.12 0.40 0.22 0.11 0.39
Other Noncurrent Operating Liabilities		 21 16 13 12 11 13 21
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 63 69 60 46 74 66 55
Total Preferred & Common Equity		 63 69 60 46 74 66 55
Total Common Equity		 63 69 60 46 74 66 55
Common Stock		 547 553 561 570 575 577 581
Retained Earnings		 -480 -479 -498 -518 -498 -509 -524
Accumulated Other Comprehensive Income / (Loss)		 -4.08 -4.90 -3.71 -5.83 -2.20 -1.78 -1.71

Annual Metrics And Ratios for Beauty Health

This table displays calculated financial ratios and metrics derived from Beauty Health's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 57,500,000.00 149,639,553.00 143,201,041.00 132,885,767.00 - 127,503,059.00
DEI Adjusted Shares Outstanding		 0.00 57,500,000.00 149,639,553.00 143,201,041.00 132,885,767.00 - 127,503,059.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.51 -2.53 0.31 -0.75 - -0.07
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -28.53% 118.39% 40.68% 8.78% -16.00% -10.02%
EBITDA Growth		 0.00% -104.08% -28,905.85% 122.10% -194.59% 101.68% 2,646.01%
EBIT Growth		 0.00% -221.55% -2,043.78% 113.43% -324.82% 67.88% 112.39%
NOPAT Growth		 0.00% -227.63% -132.38% 9.82% -263.58% 48.23% 69.31%
Net Income Growth		 0.00% -1,681.14% -1,198.25% 111.68% -326.38% 70.94% 67.29%
EPS Growth		 0.00% -1,600.00% -336.47% 93.80% -230.43% 52.63% 55.56%
Operating Cash Flow Growth		 0.00% -819.68% -128.06% -275.87% 120.40% -25.82% 132.34%
Free Cash Flow Firm Growth		 0.00% 0.00% 109.95% -1,311.13% 85.35% 80.10% 500.48%
Invested Capital Growth		 0.00% 0.00% -26.41% 155.51% -17.50% -14.85% -17.60%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 5.86% -0.33% -3.83% -0.37%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 27.61% -13.11% -73.20% 46.11%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 50.43% -12.48% 1.00% 162.52%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 10.58% -13.63% 14.19% 26.03%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 161.12% -18.63% -3.29% 18.95%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 66.67% -10.14% 16.28% -6.67%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 11.51% -8.86% 1.04% 392.92% -3.29%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -114.76% 97.84% 16.14%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 8.54% 0.00% -7.26% -8.05%
Profitability Metrics		 - - - - - - -
Gross Margin		 63.92% 56.43% 68.65% 68.00% 38.97% 54.53% 65.28%
EBITDA Margin		 17.60% -1.00% -133.38% 20.95% -18.22% 0.36% 11.11%
Operating Margin		 8.08% -14.43% -15.35% -7.06% -32.89% -20.27% -6.92%
EBIT Margin		 8.50% -14.45% -141.84% 13.54% -27.99% -10.70% 1.47%
Profit (Net Income) Margin		 -0.98% -24.50% -145.63% 12.09% -25.16% -8.70% -3.16%
Tax Burden Percent		 55.81% 75.81% 99.51% 97.54% 98.26% 98.47% 160.31%
Interest Burden Percent		 -20.73% 223.63% 103.18% 91.49% 91.45% 82.58% -133.92%
Effective Tax Rate		 0.00% 0.00% 0.00% 2.46% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -13.58% -18.18% -10.88% -30.16% -18.65% -6.83%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -30.15% -2,018.38% -2,315.21% -34.60% -9.42% -3.61%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 208.34% -259.97% 29.73% -58.27% -33.68% -10.04%
Return on Equity (ROE)		 0.00% 194.76% -278.16% 18.84% -88.42% -52.34% -16.87%
Cash Return on Invested Capital (CROIC)		 0.00% -213.58% 12.24% -98.37% -10.99% -2.61% 12.47%
Operating Return on Assets (OROA)		 0.00% -7.72% -51.18% 4.46% -11.53% -4.43% 0.75%
Return on Assets (ROA)		 0.00% -13.09% -52.55% 3.98% -10.36% -3.60% -1.61%
Return on Common Equity (ROCE)		 0.00% 194.79% -278.14% 18.84% -88.42% -52.34% -16.87%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% -56.17% 0.00%
Net Operating Profit after Tax (NOPAT)		 9.42 -12 -28 -25 -92 -47 -15
NOPAT Margin		 5.66% -10.10% -10.75% -6.89% -23.03% -14.19% -4.84%
Net Nonoperating Expense Percent (NNEP)		 0.00% 16.56% 2,000.20% 2,304.33% 4.44% -9.23% -3.21%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.45% -2.71% -2.80% -11.49% -7.85% -3.42%
Cost of Revenue to Revenue		 36.08% 43.57% 31.35% 32.00% 61.03% 45.47% 34.72%
SG&A Expenses to Revenue		 16.00% 25.74% 37.94% 29.00% 33.02% 37.53% 39.21%
R&D to Revenue		 2.77% 2.86% 3.15% 2.31% 2.54% 1.88% 1.87%
Operating Expenses to Revenue		 55.84% 70.85% 84.00% 75.06% 71.87% 74.81% 72.20%
Earnings before Interest and Taxes (EBIT)		 14 -17 -369 50 -111 -36 4.43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 29 -1.20 -347 77 -73 1.22 33
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 11.96 0.00 6.96 3.81 2.90
Price to Tangible Book Value (P/TBV)		 0.00 0.00 29.49 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.40 0.00 13.90 0.00 1.04 0.59 0.59
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 26.42 0.00 2.29 1.62 1.60
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 13.24 0.00 1.58 1.14 1.03
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 311.82 9.24
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 69.68
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 28.90 23.52 8.24
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 183.01 0.00 0.00 0.00 11.61
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 -7.23 2.41 4.39 12.43 10.66 5.97
Long-Term Debt to Equity		 0.00 -7.21 2.41 4.39 12.43 10.66 3.94
Financial Leverage		 0.00 -6.91 0.13 -0.01 1.68 3.57 2.78
Leverage Ratio		 0.00 -7.44 5.29 4.73 8.53 14.52 10.50
Compound Leverage Factor		 0.00 -16.63 5.46 4.33 7.80 11.99 -14.07
Debt to Total Capital		 0.00% 116.06% 70.71% 81.46% 92.56% 91.42% 85.65%
Short-Term Debt to Total Capital		 0.00% 0.27% 0.00% 0.00% 0.00% 0.00% 29.14%
Long-Term Debt to Total Capital		 0.00% 115.78% 70.71% 81.46% 92.56% 91.42% 56.51%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -16.06% 29.28% 18.54% 7.44% 8.58% 14.35%
Debt to EBITDA		 0.00 -181.05 -2.10 9.58 -10.18 453.74 10.90
Net Debt to EBITDA		 0.00 -173.12 0.50 2.16 -2.97 149.66 3.94
Long-Term Debt to EBITDA		 0.00 -180.62 -2.10 9.58 -10.18 453.74 7.19
Debt to NOPAT		 0.00 -18.00 -26.12 -29.13 -8.06 -11.64 -25.02
Net Debt to NOPAT		 0.00 -17.21 6.15 -6.58 -2.35 -3.84 -9.05
Long-Term Debt to NOPAT		 0.00 -17.96 -26.12 -29.13 -8.06 -11.64 -16.51
Altman Z-Score		 0.00 0.00 2.01 0.00 0.35 0.18 -0.28
Noncontrolling Interest Sharing Ratio		 0.00% -0.01% 0.01% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 1.91 13.09 10.92 6.07 7.00 1.66
Quick Ratio		 0.00 0.91 12.41 8.99 5.02 5.84 1.37
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -189 19 -228 -33 -6.64 27
Operating Cash Flow to CapEx		 19.69% -355.21% -253.20% -982.76% 568.63% 2,134.13% 12,371.29%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 1.60 -17.02 -2.45 -0.64 1.38
Operating Cash Flow to Interest Expense		 0.00 0.00 -2.41 -7.96 1.59 1.55 1.94
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -3.36 -8.77 1.31 1.48 1.92
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.53 0.36 0.33 0.41 0.41 0.51
Accounts Receivable Turnover		 0.00 6.41 7.95 5.93 6.07 8.12 12.18
Inventory Turnover		 0.00 2.24 2.79 1.62 2.42 1.89 1.78
Fixed Asset Turnover		 0.00 0.00 0.00 21.29 24.56 33.09 70.64
Accounts Payable Turnover		 0.00 2.81 3.43 4.07 6.63 4.56 5.56
Days Sales Outstanding (DSO)		 0.00 56.93 45.89 61.51 60.16 44.95 29.96
Days Inventory Outstanding (DIO)		 0.00 163.20 130.84 225.86 151.02 192.63 204.69
Days Payable Outstanding (DPO)		 0.00 130.02 106.38 89.64 55.03 80.10 65.66
Cash Conversion Cycle (CCC)		 0.00 90.11 70.35 197.73 156.14 157.48 168.99
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 177 130 333 275 234 193
Invested Capital Turnover		 0.00 1.35 1.69 1.58 1.31 1.31 1.41
Increase / (Decrease) in Invested Capital		 0.00 177 -47 203 -58 -41 -41
Enterprise Value (EV)		 0.00 0.00 3,443 0.00 629 379 309
Market Capitalization		 400 0.00 3,615 0.00 413 197 177
Book Value per Share		 $0.00 ($0.52) $2.02 $1.13 $0.45 $0.42 $0.48
Tangible Book Value per Share		 $0.00 ($3.12) $0.82 ($0.03) ($0.97) ($0.96) ($0.79)
Total Capital		 0.00 187 1,032 901 798 604 425
Total Debt		 0.00 217 730 734 738 552 364
Total Long-Term Debt		 0.00 216 730 734 738 552 240
Net Debt		 0.00 207 -172 166 215 182 132
Capital Expenditures (CapEx)		 8.77 3.50 11 11 3.83 0.76 0.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 19 23 143 60 39 15
Debt-free Net Working Capital (DFNWC)		 0.00 29 924 712 583 409 247
Net Working Capital (NWC)		 0.00 28 924 712 583 409 123
Net Nonoperating Expense (NNE)		 11 17 351 -69 8.47 -18 -5.04
Net Nonoperating Obligations (NNO)		 0.00 207 -172 166 215 182 132
Total Depreciation and Amortization (D&A)		 15 16 22 27 39 37 29
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 16.11% 8.68% 39.18% 15.13% 11.64% 4.83%
Debt-free Net Working Capital to Revenue		 0.00% 24.08% 355.44% 194.48% 146.55% 122.34% 82.18%
Net Working Capital to Revenue		 0.00% 23.65% 355.44% 194.48% 146.55% 122.34% 40.97%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.09) ($3.67) $0.30 ($0.76) ($0.23) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 57.50M 102.11M 147.55M 131.68M 123.83M 126.38M
Adjusted Diluted Earnings per Share		 $0.00 ($0.09) ($3.67) ($0.23) ($0.76) ($0.36) ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 57.50M 102.11M 148.51M 131.68M 142.49M 135.80M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.09) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 56.10M 150.60M 132.50M 123.43M 125.25M 127.77M
Normalized Net Operating Profit after Tax (NOPAT)		 9.42 -12 -28 -25 -92 -47 -15
Normalized NOPAT Margin		 5.66% -10.10% -10.75% -6.89% -23.03% -14.19% -4.84%
Pre Tax Income Margin		 -1.76% -32.31% -146.35% 12.39% -25.60% -8.84% -1.97%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -31.32 3.70 -8.16 -3.44 0.23
NOPAT to Interest Expense		 0.00 0.00 -2.37 -1.88 -6.71 -4.56 -0.75
EBIT Less CapEx to Interest Expense		 0.00 0.00 -32.27 2.89 -8.44 -3.51 0.21
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -3.32 -2.69 -6.99 -4.63 -0.77
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% -1.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -1.64% 0.00% 361.79% -30.12% 0.00% 0.00%

Quarterly Metrics And Ratios for Beauty Health

This table displays calculated financial ratios and metrics derived from Beauty Health's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 132,885,767.00 132,885,767.00 123,427,416.00 123,632,222.00 124,020,249.00 - 125,245,176.00 125,994,343.00 126,825,397.00 127,503,059.00 127,773,050.00
DEI Adjusted Shares Outstanding		 132,885,767.00 132,885,767.00 123,427,416.00 123,632,222.00 124,020,249.00 - 125,245,176.00 125,994,343.00 126,825,397.00 127,503,059.00 127,773,050.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.56 -0.07 -0.01 0.00 -0.15 - -0.08 0.16 -0.09 -0.06 -0.05
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 9.71% -1.34% -5.65% -22.88% -19.11% -13.76% -14.52% -13.70% -10.34% -1.35% -6.71%
EBITDA Growth		 -766.94% -110.57% 133.90% -24.81% 86.98% -413.95% -146.92% 232.01% 145.48% 255.54% 257.79%
EBIT Growth		 -2,837.70% -2,349.62% 85.23% -69.47% 74.54% 3.04% -165.59% 1,140.94% 70.19% 100.46% 79.94%
NOPAT Growth		 -1,882.64% -325.45% 1.84% 59.02% 73.79% 61.02% 29.24% 81.63% 70.99% 102.26% 85.02%
Net Income Growth		 -56,449.62% -248.76% 96.65% -94.00% 75.22% -9.86% -1,386.89% 9,658.42% 39.69% 21.55% 34.33%
EPS Growth		 -1,766.67% -700.00% 33.33% -433.33% 73.21% 87.50% 20.00% 130.00% 40.00% -100.00% 37.50%
Operating Cash Flow Growth		 157.21% 4.14% -29.55% -71.77% -42.58% 418.61% 117.78% 55.56% -6.48% -7.75% -285.38%
Free Cash Flow Firm Growth		 156.47% 122.08% 136.54% 151.02% -207.21% -21.19% -8.85% -32.41% 114.30% 15.34% -40.36%
Invested Capital Growth		 0.00% -17.50% -18.95% -22.42% 0.00% -14.85% -20.46% -16.71% -16.89% -17.60% -13.68%
Revenue Q/Q Growth		 -17.08% -0.61% -15.92% 11.29% -13.02% 5.96% -16.67% 12.37% -9.63% 16.58% -21.20%
EBITDA Q/Q Growth		 -721.21% 98.76% 838.98% 31.77% -207.55% 50.92% 32.54% 1,032.47% -85.27% 67.86% -31.56%
EBIT Q/Q Growth		 -6,493.02% 83.93% 69.03% 48.35% -890.54% 38.81% 15.16% 302.43% -128.37% 100.95% -3,784.91%
NOPAT Q/Q Growth		 -52.18% 77.64% 7.46% -30.13% 2.70% 66.73% -67.99% 66.22% -53.68% 102.60% -1,211.73%
Net Income Q/Q Growth		 -2,294.35% 87.26% 92.78% 129.75% -9,154.95% 43.52% 2.27% 295.25% -155.96% 26.53% 18.19%
EPS Q/Q Growth		 -1,966.67% 85.71% -25.00% 0.00% -50.00% 93.33% -700.00% 137.50% -400.00% 77.78% -150.00%
Operating Cash Flow Q/Q Growth		 -18.22% -128.78% -226.00% 136.79% 66.34% 59.69% -81.81% 221.96% 0.01% 57.52% -136.55%
Free Cash Flow Firm Q/Q Growth		 303.12% -81.79% 20.11% 14.82% -526.84% 113.39% 38.91% -14.86% -9.70% 7.99% -28.17%
Invested Capital Q/Q Growth		 -100.00% 0.00% 3.43% -4.88% -6.67% -7.26% -3.39% -0.41% -6.86% -8.05% 1.21%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -12.89% 47.19% 59.41% 45.19% 51.58% 62.69% 69.82% 62.81% 64.59% 64.39% 68.46%
EBITDA Margin		 -66.32% -0.83% 7.29% 8.63% -10.67% -4.94% -4.00% 33.20% 5.41% 7.79% 6.77%
Operating Margin		 -84.28% -18.96% -20.87% -24.41% -27.30% -8.57% -17.28% -3.45% -8.83% 0.20% -2.77%
EBIT Margin		 -75.60% -12.22% -4.50% -2.09% -23.80% -13.74% -13.99% 25.20% -7.91% 0.06% -3.01%
Profit (Net Income) Margin		 -75.78% -9.71% -0.83% 0.22% -23.21% -12.37% -14.51% 25.21% -15.61% -9.84% -10.21%
Tax Burden Percent		 104.95% 106.85% 50.75% -133.77% 111.92% 88.16% 109.69% 105.30% 103.63% 168.55% 97.30%
Interest Burden Percent		 95.51% 74.37% 36.51% 7.98% 87.16% 102.14% 94.56% 95.00% 190.43% -9,071.70% 348.90%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5.30% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -17.39% -18.10% -20.23% -52.68% -7.89% -15.29% -4.55% -8.08% 0.19% -2.73%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -15.58% -12.81% -12.14% -56.03% -10.56% -16.13% 8.26% -12.04% -5.04% -6.09%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -26.23% -25.72% -20.36% -180.62% -37.76% -59.12% 20.31% -32.32% -14.02% -19.22%
Return on Equity (ROE)		 0.00% -43.61% -43.82% -40.59% -233.30% -45.65% -74.41% 15.76% -40.41% -13.83% -21.96%
Cash Return on Invested Capital (CROIC)		 0.00% -10.99% -7.87% -6.33% -243.83% -2.61% 5.55% 5.97% 9.92% 12.47% 11.16%
Operating Return on Assets (OROA)		 0.00% -5.03% -1.92% -0.89% -11.82% -5.69% -5.94% 12.82% -3.97% 0.03% -1.55%
Return on Assets (ROA)		 0.00% -4.00% -0.36% 0.10% -11.53% -5.12% -6.16% 12.82% -7.84% -4.99% -5.27%
Return on Common Equity (ROCE)		 0.00% -43.61% -43.82% -40.59% -233.30% -45.65% -74.41% 15.76% -40.41% -13.83% -21.96%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -57 -13 -12 -15 -15 -5.01 -8.42 -2.84 -4.37 0.11 -1.26
NOPAT Margin		 -59.00% -13.27% -14.61% -17.08% -19.11% -6.00% -12.10% -3.64% -6.18% 0.14% -1.94%
Net Nonoperating Expense Percent (NNEP)		 0.00% -1.81% -5.29% -8.09% 3.36% 2.68% 0.84% -12.81% 3.96% 5.24% 3.36%
Return On Investment Capital (ROIC_SIMPLE)		 - -1.61% -1.63% -2.50% -2.46% -0.83% -1.40% -0.65% -1.02% 0.03% -0.32%
Cost of Revenue to Revenue		 112.89% 52.81% 40.59% 54.81% 48.42% 37.31% 30.18% 37.19% 35.41% 35.61% 31.54%
SG&A Expenses to Revenue		 37.96% 29.93% 35.45% 34.67% 42.43% 38.03% 48.24% 35.11% 41.40% 33.61% 33.81%
R&D to Revenue		 1.89% 3.15% 3.45% 1.28% 1.41% 1.46% 1.43% 1.60% 2.40% 2.04% 1.70%
Operating Expenses to Revenue		 71.40% 66.15% 80.28% 69.60% 78.89% 71.27% 87.10% 66.27% 73.42% 64.19% 71.24%
Earnings before Interest and Taxes (EBIT)		 -74 -12 -3.67 -1.89 -19 -11 -9.73 20 -5.59 0.05 -1.95
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -65 -0.80 5.93 7.82 -8.41 -4.13 -2.78 26 3.82 6.42 4.39
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 6.96 8.66 3.43 2.99 3.81 3.64 3.25 3.84 2.90 2.06
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.00 1.04 1.39 0.65 0.51 0.59 0.52 0.78 0.84 0.59 0.38
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 2.29 2.71 1.62 1.47 1.62 1.54 1.74 1.89 1.60 1.30
Enterprise Value to Revenue (EV/Rev)		 0.00 1.58 1.96 1.20 1.07 1.14 1.08 1.26 1.31 1.03 0.86
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 81.72 311.82 0.00 36.82 17.33 9.24 6.25
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 69.68 20.76
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 28.90 42.94 204.79 0.00 23.52 9.66 9.94 10.23 8.24 8.76
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 24.55 26.48 17.30 11.61 10.79
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 12.43 10.51 7.96 9.23 10.66 12.01 4.91 5.53 5.97 6.23
Long-Term Debt to Equity		 0.00 12.43 10.51 7.96 9.23 10.66 12.01 4.91 5.53 3.94 4.37
Financial Leverage		 0.00 1.68 2.01 1.68 3.22 3.57 3.67 2.46 2.68 2.78 3.16
Leverage Ratio		 0.00 8.53 8.72 7.44 11.71 14.52 13.89 8.52 9.60 10.50 11.32
Compound Leverage Factor		 0.00 6.35 3.18 0.59 10.21 14.83 13.13 8.09 18.27 -952.90 39.51
Debt to Total Capital		 0.00% 92.56% 91.31% 88.84% 90.23% 91.42% 92.31% 83.07% 84.70% 85.65% 86.17%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 29.14% 25.77%
Long-Term Debt to Total Capital		 0.00% 92.56% 91.31% 88.84% 90.23% 91.42% 92.31% 83.07% 84.70% 56.51% 60.40%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 7.44% 8.69% 11.16% 9.77% 8.58% 7.69% 16.93% 15.30% 14.35% 13.83%
Debt to EBITDA		 0.00 -10.18 -13.56 -10.66 121.43 453.74 -73.72 34.13 15.89 10.90 8.48
Net Debt to EBITDA		 0.00 -2.97 -4.50 -3.89 42.40 149.66 -23.99 14.20 6.30 3.94 3.45
Long-Term Debt to EBITDA		 0.00 -10.18 -13.56 -10.66 121.43 453.74 -73.72 34.13 15.89 7.19 5.94
Debt to NOPAT		 0.00 -8.06 -7.28 -5.64 -9.97 -11.64 -12.58 -11.95 -18.46 -25.02 -46.47
Net Debt to NOPAT		 0.00 -2.35 -2.42 -2.06 -3.48 -3.84 -4.09 -4.97 -7.31 -9.05 -18.88
Long-Term Debt to NOPAT		 0.00 -8.06 -7.28 -5.64 -9.97 -11.64 -12.58 -11.95 -18.46 -16.51 -32.58
Altman Z-Score		 0.00 0.70 0.82 0.48 0.29 0.30 0.24 0.28 0.08 -0.31 -0.46
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 6.07 6.57 6.49 6.56 7.00 7.47 5.15 4.98 1.66 1.79
Quick Ratio		 0.00 5.02 5.26 5.18 5.34 5.84 6.31 3.99 3.90 1.37 1.44
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 249 45 55 63 -267 36 50 42 38 41 30
Operating Cash Flow to CapEx		 10,324.14% -18,464.29% -4,899.42% 1,856.59% 257,875.00% 22,259.46% 6,657.78% 10,484.78% 35,729.63% 10,932.37% -2,479.46%
Free Cash Flow to Firm to Interest Expense		 72.37 13.52 18.01 25.54 -108.31 14.53 19.90 10.21 6.06 6.48 4.67
Operating Cash Flow to Interest Expense		 5.21 -1.54 -5.56 2.53 4.18 6.69 1.20 2.33 1.53 2.38 -0.88
Operating Cash Flow Less CapEx to Interest Expense		 5.16 -1.55 -5.68 2.39 4.18 6.66 1.18 2.31 1.52 2.36 -0.91
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.41 0.43 0.43 0.50 0.41 0.42 0.51 0.50 0.51 0.52
Accounts Receivable Turnover		 0.00 6.07 6.64 6.31 9.58 8.12 9.09 9.33 10.32 12.18 14.14
Inventory Turnover		 0.00 2.42 2.24 2.65 2.34 1.89 1.73 1.75 1.64 1.78 1.83
Fixed Asset Turnover		 0.00 24.56 25.86 26.47 45.54 33.09 39.64 46.20 56.50 70.64 90.34
Accounts Payable Turnover		 0.00 6.63 6.80 8.70 7.45 4.56 4.63 4.81 5.26 5.56 5.32
Days Sales Outstanding (DSO)		 0.00 60.16 54.99 57.83 38.09 44.95 40.14 39.11 35.35 29.96 25.81
Days Inventory Outstanding (DIO)		 0.00 151.02 163.07 137.84 155.87 192.63 210.40 208.42 222.60 204.69 199.06
Days Payable Outstanding (DPO)		 0.00 55.03 53.64 41.97 48.99 80.10 78.83 75.92 69.36 65.66 68.55
Cash Conversion Cycle (CCC)		 0.00 156.14 164.43 153.70 144.97 157.48 171.71 171.61 188.59 168.99 156.31
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 275 284 270 252 234 226 225 210 193 195
Invested Capital Turnover		 0.00 1.31 1.24 1.18 2.76 1.31 1.26 1.25 1.31 1.41 1.41
Increase / (Decrease) in Invested Capital		 -307 -58 -66 -78 252 -41 -58 -45 -43 -41 -31
Enterprise Value (EV)		 0.00 629 769 438 371 379 348 392 396 309 254
Market Capitalization		 800 413 548 237 179 197 168 241 252 177 114
Book Value per Share		 $0.00 $0.45 $0.51 $0.56 $0.48 $0.42 $0.37 $0.59 $0.52 $0.48 $0.43
Tangible Book Value per Share		 $0.00 ($0.97) ($0.98) ($0.89) ($0.94) ($0.96) ($0.99) ($0.76) ($0.78) ($0.79) ($0.81)
Total Capital		 0.00 798 729 620 611 604 599 437 429 425 399
Total Debt		 0.00 738 665 551 551 552 553 363 363 364 344
Total Long-Term Debt		 0.00 738 665 551 551 552 553 363 363 240 241
Net Debt		 0.00 215 221 201 193 182 180 151 144 132 140
Capital Expenditures (CapEx)		 0.17 0.03 0.34 0.33 0.00 0.07 0.05 0.09 0.03 0.14 0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 60 77 65 52 39 34 35 27 15 21
Debt-free Net Working Capital (DFNWC)		 0.00 583 521 414 411 409 407 247 246 247 225
Net Working Capital (NWC)		 0.00 583 521 414 411 409 407 247 246 123 122
Net Nonoperating Expense (NNE)		 16 -3.45 -11 -16 3.23 5.32 1.68 -23 6.66 8.22 5.37
Net Nonoperating Obligations (NNO)		 0.00 215 221 201 193 182 180 151 144 132 140
Total Depreciation and Amortization (D&A)		 9.04 11 9.60 9.71 10 7.35 6.95 6.26 9.41 6.37 6.35
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 15.13% 19.49% 17.65% 15.02% 11.64% 10.40% 11.18% 8.96% 4.83% 7.12%
Debt-free Net Working Capital to Revenue		 0.00% 146.55% 132.60% 113.10% 118.26% 122.34% 126.08% 79.55% 81.63% 82.18% 76.13%
Net Working Capital to Revenue		 0.00% 146.55% 132.60% 113.10% 118.26% 122.34% 126.08% 79.55% 81.63% 40.97% 41.37%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.08) ($0.01) $0.00 ($0.15) ($0.07) ($0.08) $0.16 ($0.09) ($0.07) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 131.68M 123.12M 123.72M 124.06M 123.83M 125.08M 126.07M 126.89M 126.38M 127.79M
Adjusted Diluted Earnings per Share		 $0.00 ($0.08) ($0.10) ($0.10) ($0.15) ($0.01) ($0.08) $0.03 ($0.09) ($0.02) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 131.68M 144.48M 141.93M 124.06M 142.49M 125.08M 140.29M 126.89M 135.80M 131.40M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 123.43M 123.63M 124.02M 124.12M 125.25M 125.99M 126.83M 127.50M 127.77M 129.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -57 -13 -12 -15 -15 -5.01 -8.42 -1.89 -4.37 0.11 -1.26
Normalized NOPAT Margin		 -59.00% -13.27% -14.61% -17.08% -19.11% -6.00% -12.10% -2.42% -6.18% 0.14% -1.94%
Pre Tax Income Margin		 -72.21% -9.09% -1.64% -0.17% -20.74% -14.03% -13.23% 23.94% -15.07% -5.84% -10.50%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -21.38 -3.52 -1.21 -0.77 -7.60 -4.66 -3.90 4.76 -0.89 0.01 -0.31
NOPAT to Interest Expense		 -16.68 -3.83 -3.93 -6.31 -6.10 -2.03 -3.37 -0.69 -0.69 0.02 -0.20
EBIT Less CapEx to Interest Expense		 -21.43 -3.53 -1.32 -0.91 -7.60 -4.69 -3.91 4.73 -0.89 -0.01 -0.34
NOPAT Less CapEx to Interest Expense		 -16.73 -3.84 -4.04 -6.45 -6.10 -2.06 -3.39 -0.71 -0.70 0.00 -0.23
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -30.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Beauty Health Co. (NASDAQ: SKIN) has shown a meaningful shift over the last four years: revenue has been volatile and profitability remains inconsistent, but the company’s balance sheet is much more manageable than it was in early 2024. The most important recent development is that SKIN entered Q1 2026 with a large cash balance and a much smaller equity deficit than in prior periods, even though operating losses and leverage still remain material concerns.

  • Cash improved sharply from year-ago levels. SKIN ended Q1 2026 with $204.4 million in cash and equivalents, versus $373.0 million a year earlier and $219.4 million in Q3 2025. While the balance is down from 2024 peaks, it still gives the company a meaningful liquidity cushion.
  • Equity has recovered materially from prior stress levels. Total common equity was $55.2 million in Q1 2026, up from $46.1 million in Q1 2024 and well above the levels seen during the worst balance-sheet pressure periods. That suggests the company has stabilized somewhat.
  • Revenue held relatively steady year over year in Q1 2026. Q1 2026 revenue of $64.9 million was down from $69.6 million in Q1 2025, but the decline was not as severe as the company’s earlier swings, indicating some degree of demand stabilization.
  • Gross profit remains solid despite weak net results. Q1 2026 gross profit was $44.4 million, with gross margin around 68%, showing that the core product business still generates decent margin before operating expenses.
  • Operating cash flow was still negative in Q1 2026, but financing debt paydown is reducing balance-sheet risk. The company repaid $20.2 million of debt in the quarter, which should gradually lower interest burden if operations can improve.
  • Inventory is lower than many prior periods. Inventories fell to $47.7 million in Q1 2026 from $65.6 million in Q1 2025, suggesting less working-capital buildup than before.
  • Revenue has been inconsistent over the last several quarters. SKIN posted $90.6 million in Q2 2024, $78.2 million in Q2 2025, $70.7 million in Q3 2025, and $82.4 million in Q4 2025 before falling back to $64.9 million in Q1 2026. The trend lacks a clear, durable growth pattern.
  • Noncash charges remain a major part of earnings. Amortization and depreciation continue to be sizable, which means reported earnings do not translate cleanly into cash generation.
  • Goodwill and intangible assets still make up a large portion of the asset base. In Q1 2026, goodwill was $126.2 million and intangible assets were $33.0 million, so a meaningful part of assets is tied to acquisitions and accounting intangibles rather than hard assets.
  • The company’s share count has been relatively stable. Basic weighted-average shares outstanding were 127.8 million in Q1 2026, not far from prior quarters, so dilution is not currently the biggest issue.
  • SKIN remains unprofitable. Q1 2026 net loss was $6.6 million, following a $8.1 million loss in Q4 2025 and a $11.0 million loss in Q3 2025. Profitability is still elusive.
  • Operating losses continue despite decent gross margins. Q1 2026 operating loss was $1.8 million, and the company has frequently posted much larger operating losses in recent quarters and years.
  • Interest expense remains a heavy burden. Q1 2026 interest expense was $6.3 million versus only $1.5 million of interest and investment income, underscoring how debt still weighs on results.
  • Leverage is still significant. Q1 2026 showed $102.9 million of short-term debt and $241.3 million of long-term debt, so the company is still carrying a sizable debt load.
  • Operating cash flow weakened versus prior periods. Q1 2026 operating cash flow was negative $5.6 million, compared with positive $15.2 million in Q4 2025 and $9.6 million in Q3 2025, indicating a softer start to the year.
  • The balance sheet has shrunk materially since early 2024. Total assets fell from $844.7 million in Q1 2024 to $473.2 million in Q1 2026, while liabilities also fell but remain very large. That reflects a significantly reduced financial footprint.

Bottom line: Beauty Health has made progress on liquidity and has reduced some of the extreme balance-sheet pressure seen in earlier periods, but the business is still not consistently profitable and still carries meaningful debt. For retail investors, SKIN looks more stable than it did a year ago, but it is not yet a clear turnaround story until revenue and operating cash flow improve in a sustained way.

07/14/26 11:11 PM ETAI Generated. May Contain Errors.

Beauty Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Beauty Health's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Beauty Health's net income appears to be on a downward trend, with a most recent value of -$9.52 million in 2025, rising from -$1.64 million in 2019. The previous period was -$29.10 million in 2024. See Beauty Health's forecast for analyst expectations on what's next for the company.

Beauty Health's total operating income in 2025 was -$20.80 million, based on the following breakdown:
  • Total Gross Profit: $196.36 million
  • Total Operating Expenses: $217.17 million

Over the last 6 years, Beauty Health's total revenue changed from $166.62 million in 2019 to $300.79 million in 2025, a change of 80.5%.

Beauty Health's total liabilities were at $438.75 million at the end of 2025, a 30.8% decrease from 2024, and a 73.6% increase since 2020.

In the past 5 years, Beauty Health's cash and equivalents has ranged from $9.49 million in 2020 to $901.89 million in 2021, and is currently $232.67 million as of their latest financial filing in 2025.

Over the last 6 years, Beauty Health's book value per share changed from 0.00 in 2019 to 0.48 in 2025, a change of 47.9%.


Related Companies

Financial statements for NASDAQ:SKIN last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
How much money does your next trade really require?
If a stock trades at $300, most investors assume they need $300 per share. Sean Allison says that assumption m...
Trade Thirsty | Sponsoredtc pixel
60 years. Zero competitors.
One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...
Behind the Markets | Sponsoredtc pixel
SpaceX Opens Up 11% — Here’s What You Need to Know
SpaceX - ticker SPCX - just completed the biggest IPO in American history, raising $75 billion at a $1.8 trill...
Porter & Company | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
ALT SL: These Two Men Who Picked Nvidia Say: “Buy this Elon Supplier”
Jeff Brown and Marc Chaikin - the two investors who picked Nvidia before it climbed as much as 36,000% - are i...
Brownstone Research | Sponsoredtc pixel
Print this and keep it by your screen
Ever been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...
Profits Run | Sponsoredtc pixel